drugset
drugset / Trial / NCT02879877

A First-In-Human Study With a Single Ascending Dose of UCB7858 in Healthy Volunteers

NCT02879877 ↗

Phase 1 Completed 78 enrolled UCB Biopharma S.P.R.L.
RandomizedParallel-groupQuadruple-blindBasic science

Summary

This study is designed to evaluate the safety and tolerability of UCB7858 when given as single ascending doses administered by intravenous or subcutaneous infusion in healthy subjects.

Timeline

Start
2016-07-11
Primary completion
2018-01-31
Completion
2018-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject UCB7858 Unknown — Intravenous

Indications

No indication recorded.